NCT03925935View on ClinicalTrials.gov

Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 7, 2019

Primary Completion Date

November 18, 2020

Study Completion Date

November 8, 2021

Conditions
Hodgkin LymphomaNon-hodgkin Lymphoma
Interventions
BIOLOGICAL

AB-205

Engineered human umbilical vein endothelial cells

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Vanderbilt-Ingram Cancer Center, Nashville

48109

University of Michigan, Ann Arbor

77030

MD Anderson, Houston

91010

City of Hope Comprehensive Cancer Center, Duarte

92093

UC San Diego Moores Cancer Center, San Diego

94117

The University of California San Francisco, San Francisco

95817

UC Davis Comprehensive Cancer Center, Sacramento

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Angiocrine Bioscience

INDUSTRY